KA
Kaya Holdings, Inc.
KAYS · OTC
$0.00 +0.00% (+$0.00)
1M +1,200.00%
Market Cap $4.16K
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0
100.0% downside
Current Price
$0.0013
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KAYS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S -3.15x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 79.99%
EPS growth N/A
FCF growth N/A
Profitability
80 /100
Strong Gross margin 319.58%
Net margin 891,468.00%
Op. margin 74,744.50%
Quality
57 /100
Average ROIC 46.01%
ROA 5,893.70%
Asset turnover -0.01x
Debt
0 /100
High Current ratio 0.04x
Int. coverage -7.58x
Debt/Equity N/A
Stability
25 /100
Unstable Beta 0.53x
Rev. volatility 37.31%
EPS volatility 478.34%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KAYS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Craig R. Frank
Employees
2
Headquarters
Boca Raton